Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/tumoricidal-activity-of-tumor-necrosis-factor-related-apoptosis-0mg9v0Wbuw
References (48)
-
M. Hahne, D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. French, P. Schneider, Thierry Bornand, A. Fontana, D. Liénard, J. Cerottini, J. Tschopp (1996)
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 274
-
W. Fiers (1991)
Tumor necrosis factor Characterization at the molecular, cellular and in vivo levelFEBS Letters, 285
-
S. Ju, D. Panka, Haili Cui, R. Ettinger, Maan EI-Khatib, D. Sherr, B. Stanger, A. Marshak‐Rothstein (1995)
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 373
-
M. Revel, A. Schattner (2007)
Interferons: cytokines in autoimmunity.Ciba Foundation symposium, 129
-
S. Mariani, B. Matiba, E. Armandola, P. Krammer (1997)
Interleukin 1β-converting Enzyme Related Proteases/Caspases Are Involved in TRAIL-induced Apoptosis of Myeloma and Leukemia CellsThe Journal of Cell Biology, 137
-
B. Matiba, Sara Mariani, P. Krammer (1997)
The CD95 system and the death of a lymphocyte.Seminars in immunology, 9 1
-
D. Kägi, B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. Olsen, E. Podack, R. Zinkernagel, H. Hengartner (1994)
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient miceNature, 369
-
S. Wiley, K. Schooley, P. Smolak, W. Din, Changwei Huang, J. Nicholl, G. Sutherland, T. Smith, C. Rauch, Craig Smith, R. Goodwin (1995)
Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity, 3 6
-
M. Elliott, R. Maini, M. Feldmann, J. Kalden, C. Antoni, J. Smolen, B. Leeb, F. Breedveld, J. Macfarlane, J. Bijl, J. Woody (1994)
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 344
-
H. Walczak, M. Degli-Esposti, Richard Johnson, P. Smolak, Jennifer Waugh, N. Boiani, Martin Timour, M. Gerhart, K. Schooley, Craig Smith, R. Goodwin, C. Rauch (1997)
TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAILThe EMBO Journal, 16
-
M. Degli-Esposti, P. Smolak, H. Walczak, Jennifer Waugh, Changwei Huang, R. Dubose, R. Goodwin, Craig Smith (1997)
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor FamilyThe Journal of Experimental Medicine, 186
-
T. Griffith, Wilson Chin, Glenn Jackson, D. Lynch, M. Kubin (1998)
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.Journal of immunology, 161 6
-
G. Alderson, T. Tough, T. Davis‐Smith, Steve Braddy, Ben Falk, Ken Schooley, Raymond Goodwin, Craig Smith, Fred Ramsdell, David Lynch (1995)
Fas ligand mediates activation-induced cell death in human T lymphocytesThe Journal of Experimental Medicine, 181
-
L. Moreland, Scott Baumgartner, M. Schiff, E. Tindall, R. Fleischmann, A. Weaver, R. Ettlinger, S. Cohen, W. Koopman, K. Mohler, M. Widmer, C. Blosch (1997)
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.The New England journal of medicine, 337 3
-
Masato Tanaka, Masato Tanaka, T. Suda, T. Yatomi, N. Nakamura, S. Nagata (1997)
Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes.Journal of immunology, 158 5
-
Lixin Zheng, G. Fisher, Robert Miller, J. Peschon, D. Lynch, M. Lenardo (1995)
Induction of apoptosis in mature T cells by tumour necrosis factorNature, 377
-
W. Fanslow, S. Srinivasan, Raymond Paxton, Marylou Gibson, M. Spriggs, R. Armitage (1994)
Structural characteristics of CD40 ligand that determine biological function.Seminars in immunology, 6 5
-
L. Old (1985)
Tumor necrosis factor (TNF).Science, 230 4726
-
G. Fisher, Fredric Rosenberg, S. Straus, J. Dale, L. Middelton, A. Lin, W. Strober, M. Lenardo, J. Puck (1995)
Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndromeCell, 81
-
Marcus Peter, A. Ehret, Christina Berndt, P. Krammer (1997)
AIDS and the death receptors.British medical bulletin, 53 3
-
S. Strand, W. Hofmann, H. Hug, Martina Müller, G. Otto, D. Strand, S. Mariani, W. Stremmel, P. Krammer, P. Galle (1996)
Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?Nature Medicine, 2
-
Peter Vandenabeele, W. Declercq, Bart Vanhaesebroeck, J. Grooten, W. Fiers (1995)
Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells.Journal of immunology, 154 6
-
D. Bellgrau, D. Gold, H. Selawry, Jodene Moore, A. Franzusoff, R. Duke (1995)
A role for CD95 ligand in preventing graft rejectionNature, 377
-
S. Marsters, J. Sheridan, R. Pitti, A. Huang, M. Skubatch, Daryl Baldwin, Yuan Jean, A. Gurney, A. Goddard, P. Godowski, A. Ashkenazi (1997)
A novel receptor for Apo2L/TRAIL contains a truncated death domainCurrent Biology, 7
-
P. Galle, W. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. Krammer, L. Runkel (1995)
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damageThe Journal of Experimental Medicine, 182
-
P. Schneider, N. Holler, J. Bodmer, M. Hahne, K. Frei, A. Fontana, J. Tschopp (1998)
Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver ToxicityThe Journal of Experimental Medicine, 187
-
J. Sheridan, S. Marsters, R. Pitti, A. Gurney, M. Skubatch, Daryl Baldwin, Lakshmi Ramakrishnan, C. Gray, K. Baker, W. Wood, A. Goddard, P. Godowski, A. Ashkenazi (1997)
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.Science, 277 5327
-
R. Armitage (1994)
Tumor necrosis factor receptor superfamily members and their ligands.Current opinion in immunology, 6 3
-
J. Emery, P. Mcdonnell, M. Burke, K. Deen, S. Lyn, C. Silverman, E. Dul, E. Appelbaum, C. Eichman, R. DiPrinzio, R. Dodds, I. James, Martin Rosenberg, John Lee, P. Young (1998)
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*The Journal of Biological Chemistry, 273
-
G. Pan, K. O’Rourke, A. Chinnaiyan, R. Gentz, R. Ebner, Jian Ni, V. Dixit (1997)
The Receptor for the Cytotoxic Ligand TRAIL, 276
-
B. Lowin, M. Hahne, C. Mattmann, J. Tschopp (1994)
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathwaysNature, 370
-
J. Ogasawara, Rie Watanabe‐Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, S. Nagata (1993)
Lethal effect of the anti-Fas antibody in miceNature, 364
-
T. Brunner, R. Mogil, D. Laface, N. Yoo, A. Mahboubi, F. Echeverri, Seamus Martin, W. Force, D. Lynch, C. Ware, D. Green (1995)
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomasNature, 373
-
T. Griffith, T. Brunner, Sharon Fletcher, D. Green, T. Ferguson (1995)
Fas Ligand-Induced Apoptosis as a Mechanism of Immune PrivilegeScience, 270
-
S. Nagata (1997)
Apoptosis by Death FactorCell, 88
-
J. Cohen (1988)
Cytokines as mediators of graft-versus-host disease.Bone marrow transplantation, 3 3
-
D. Cosman (1994)
A family of ligands for the TNF receptor superfamilySTEM CELLS, 12
-
Anthony Ceramil, B. Beutler (1988)
The role of cachectin/TNF in endotoxic shock and cachexia.Immunology today, 9 1
-
J. Dhein, H. Walczak, C. Bäumler, K. Debatin, P. Krammer (1995)
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 373
-
F. Brennan, M. Feldmann (1992)
Cytokines in autoimmunity.Current opinion in immunology, 8 6
-
Craig Smith, T. Farrah, R. Goodwin (1994)
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and deathCell, 76
-
G. Pan, Jian Ni, Ying-Fei Wei, Guo-liang Yu, Reiner Gentz, V. Dixit (1997)
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.Science, 277 5327
-
M. Degli-Esposti, W. Dougall, P. Smolak, Jennifer Waugh, Craig Smith, R. Goodwin (1997)
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.Immunity, 7 6
-
T. Kondo, T. Suda, H. Fukuyama, M. Adachi, S. Nagata (1997)
Essential roles of the Fas ligand in the development of hepatitisNature Medicine, 3
-
E. Havell, Walter Fiers, R. North (1988)
The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicityThe Journal of Experimental Medicine, 167
-
L. French, M. Hahne, Isabeue Viard, G. Radlgruber, R. Zanone, Karin Becker, Christian Miiller, J. Tschopp (1996)
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnoverThe Journal of Cell Biology, 133
-
P. Brouckaert, G. Leroux-Roels, Y. Guisez, J. Tavernier, W. Fiers (1986)
In vivo anti‐tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN‐γ, on a syngeneic murine melanomaInternational Journal of Cancer, 38
-
R. Pitti, S. Marsters, S. Ruppert, C. Donahue, A. Moore, A. Ashkenazi (1996)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*The Journal of Biological Chemistry, 271
- Publisher
- Springer Journals
- Copyright
- Copyright © 1999 by Nature America Inc.
- Subject
- Biomedicine; Biomedicine, general; Cancer Research; Metabolic Diseases; Infectious Diseases; Molecular Medicine; Neurosciences
- ISSN
- 1078-8956
- eISSN
- 1546-170X
- DOI
- 10.1038/5517
- Publisher site
- See Article on Publisher Site
Abstract
To evaluate the utility of tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ–huCD95L in vivo, administration of either LZ–huTRAIL or LZ–muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ–huTRAIL actively suppressed growth of the TRAIL–sensitive human mammary adenocarcinoma cell line MDA–231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ–huTRAIL demonstrated clear areas of apoptotic necrosis within 9–12 hours of injection.
Journal
Nature Medicine – Springer Journals
Published: Feb 1, 1999